| 摘要 |
The invention refers to medicine, namely to the clinical biochemistry, and can be used for differential diagnostics of dyshormonal hyperplasiae and mammary cancer. Summary of the invention consists in that it is determined the content of the reduced glutathione (GSH), activity of glutathione-S-transferase (GST), glutathione reductase (GR), gamma-glutamyltranspeptidase (GGT) and glucose-6-phosphate dehydrogenase (G6 PDH) in the blood plasma and in saliva, there are determined the ratios GR/G6PDH, GR/GST, GR/GGT and GR/GSH and where in saliva is determined: GR/G6PDH from 1,89 up to 2,94; GR/GST from 0,41 up to 0,54; GR/GGT from 4,83 up to 8,70; GR/GSH from 333,0 up to 454,0; and in saliva: GR/G6PDH from 1,41 up to 2,21; GR/GST from 0,34 up to 0,42; GR/GGT from 1,62 up to 2,59; GR/GSH from 613,0 up to 663,2 it is diagnosed the dyshormonal hyperplasia of mammary gland, and where in plasma is determined: GR/G6PDH from 0,84 up to 1,89; GR/GST from 0,29 up to 0,41; GR/GGT from 0,96 up to 4,83; GR/GSH from 212,0 up to 333,0; and in saliva: GR/G6PDH from 0,61 up to 1,41; GR/GST from 0,26 up to 0,34; GR/GGT from 0,65 up to 1,62; GR/GSH from 562,8 up to 613,0 it is diagnosed the mammary cancer.
|
